Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib plus aromatase inhibitor in HR+ HER2- metastatic breast cancer
NCT02246621Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2014
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Abemaciclib + NSAI with Placebo + NSAI (2 arms). Primary endpoint: Progression-Free Survival at 32 months. Started Nov 2014; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02246621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02246621.